Beijing Wantai Biological Pharmacy Enterprise Balance Sheet Health
Financial Health criteria checks 4/6
Beijing Wantai Biological Pharmacy Enterprise has a total shareholder equity of CN¥12.7B and total debt of CN¥238.8M, which brings its debt-to-equity ratio to 1.9%. Its total assets and total liabilities are CN¥15.0B and CN¥2.2B respectively.
Key information
1.9%
Debt to equity ratio
CN¥238.81m
Debt
Interest coverage ratio | n/a |
Cash | CN¥5.62b |
Equity | CN¥12.74b |
Total liabilities | CN¥2.23b |
Total assets | CN¥14.96b |
Recent financial health updates
Recent updates
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) Analysts Are Reducing Their Forecasts For This Year
Jul 26These 4 Measures Indicate That Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Is Using Debt Reasonably Well
Jul 22Some Investors May Be Willing To Look Past Beijing Wantai Biological Pharmacy Enterprise's (SHSE:603392) Soft Earnings
Apr 04Things Look Grim For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) After Today's Downgrade
Apr 02Earnings Tell The Story For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) As Its Stock Soars 27%
Feb 28Financial Position Analysis
Short Term Liabilities: 603392's short term assets (CN¥9.2B) exceed its short term liabilities (CN¥2.1B).
Long Term Liabilities: 603392's short term assets (CN¥9.2B) exceed its long term liabilities (CN¥174.6M).
Debt to Equity History and Analysis
Debt Level: 603392 has more cash than its total debt.
Reducing Debt: 603392's debt to equity ratio has increased from 0.05% to 1.9% over the past 5 years.
Debt Coverage: 603392's debt is well covered by operating cash flow (628.2%).
Interest Coverage: Insufficient data to determine if 603392's interest payments on its debt are well covered by EBIT.